OKYO Pharma LTD

Our CEO and CSO will be presenting in Denver. Join us to learn more about Urcosimod, an investigational therapy in clinical development for neuropathic corneal pain (NCP), an area with no approved treatments today. Presentation Title: Addressing Unmet Needs in Corneal and Anterior Segment Diseases 📅 Friday May 1, 2026 🕣2:10-2:15 PM MDT 📍Breakout: Anterior Segment, Room 401 Presenter: Robert J. Dempsey, Chief Executive Officer at OKYO Pharma Presentation Title: First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients 📅 Tuesday May 5, 2026, 🕣3:30 PM to 5:15 PM MDT 📍Poster Presentation/Board: 3461/0044 Presenter: Raj Patil, PhD, Chief Scientific Officer at OKYO Pharma $OKYO #Eyecelerator #ARVO2026 #NCP #Innovation #Education #Ophthalmology #Optometry okyopharma.com/okyo-ceo-and-c…

OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During @ASCRStweets Annual Meeting. We look forward to engaging with colleagues and exchanging meaningful insights with leading clinical experts in DC. Paper presentation: "Evaluation of Urcosimod in Neuropathic Corneal Pain: Efficacy and Safety Results from a Proof-of-Concept Pilot Phase 2 Study” 📅 Saturday, April 11, 2026 📍 ASCRS Ocular Disease II Session 🕣 3:30-5:00pm Learn more here okyopharma.com/okyo-pharma-an… $OKYO #NCP #Urcoismod #NeuropathicCornealPain #ASCRS2026 #Ophthalmology #Optometry #ScientificAdvisoryBoard

OKYO today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 10,119 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. $OKYO okyopharma.com/okyo-pharma-an…

OKYO today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company’s ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. $OKYO okyopharma.com/okyo-pharma-an…

OKYO has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares. $OKYO okyopharma.com/okyo-pharma-an…

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain. After 12 weeks of treatment, patients receiving urcosimod demonstrated greater improvements across key aspects of emotional well-being and quality of life compared to placebo. This new quality-of-life (QoL) data will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. $OKYO #NCP #Urcoismod #NeuropathicCornealPain #Urcosimod #Ophthalmology #Optometry okyopharma.com/okyo-pharma-re…

OKYO Abstract Selected for Presentation at ARVO 2026, a Premier Global Ophthalmology Congress. Chief Scientific Officer Raj Patil, Ph.D., will share the data in a presentation titled: "First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients." $OKYO #ARVO2026 #NeuropathicCornealPain #Urcosimod #Ophthalmology #Optometry #NCP okyopharma.com/okyo-pharma-an…

Exciting developments at OKYO Pharma! We're thrilled to announce the pricing of our $20 million underwritten public offering of 10,815,000 ordinary shares at $1.85 per share. This offering, expected to close on or about February 17, 2026, includes an underwriter option for up to an additional 1,622,250 shares and represents a significant step forward in fueling our mission to advance innovative therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases. We have recently also strengthened our leadership team with two key appointments that bring world-class expertise to drive our clinical programs. In January, we welcomed Robert Dempsey as our new Chief Executive Officer, leveraging his over two decades of experience in the biopharma industry to guide our strategic growth. More recently, in February, Flavio Mantelli, MD, PhD, joined as Chief Medical Officer, bringing his proven track record in ocular therapeutics to accelerate our urcosimod program for NCP. These milestones underscore our commitment to innovation and patient impact. Stay tuned for more updates as we push boundaries in eye care! globenewswire.com/news-release/2… $OKYO

We are proud to announce the appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer to further strengthen our world class leadership team. Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal disease setting a new benchmark for orphan drug clinical development. In his new role at OKYO Pharma, Dr. Mantelli will oversee the company's clinical development strategy, including the advancement of urcosimod in planned clinical trials for neuropathic corneal pain and additional orphan indications. Dr. Mantelli intends to build upon the recent FDA alignment with the proposed Phase 2b/3 design, to help ensure the upcoming trial is positioned as a potential pivotal study to bring this important therapy to patients with no FDA approved therapy. $OKYO #ExecutiveLeadership #Biopharma #LeadershipTeam #PipelineProgress #CompanyGrowth #NeuropathicCornealPain #NCP #Urcosimod #Ophthalmology #Optometry okyopharma.com/okyo-pharma-st…

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting. This acceptance follows a rigorous and highly competitive review process by the ASCRS Annual Meeting Program Committee, where only a limited number of submissions are selected each year. $OKYO #ASCRS2026 #Ophthalmology #OKYOPharma #Biotech #Optometry #NCP #Innovation #ClinicalTrial #NeuropathicCornealPain #Urcosimod okyopharma.com/okyo-pharma-an…

OKYO Pharma clears key FDA meeting for Urcosimod Phase 2b/3 Trial @OkyoPharma proactiveinvestors.com/companies/news… #proactiveinvestors #okyopharmalimited #nasdaq #okyo #Urcosimod

OKYO Pharma Announces Successful Type C Meeting with the FDA. The FDA have confirmed Phase 2b/3 clinical design, including primary endpoint, sample size, and development approach. “We were very pleased to achieve meaningful progress with the FDA toward alignment on urcosimod’s clinical development program,” said Raj Patil, Ph.D., Chief Scientific Officer at OKYO Pharma. “This alignment represents an important step forward and underscores the potential to address a significant unmet medical need in patients with neuropathic corneal pain.” $OKYO #OKYOPharma #Biotech #Ophthalmology #Optometry #NCP #Innovation #FDA #ClinicalTrial #NeuropathicCornealPain #Urcosimod okyopharma.com/okyo-pharma-an…

FDA Authorizes Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain. The FDA has authorized a single-patient expanded access IND application submitted by Pedram Hamrah, MD, at the University of South Florida, for the use of urcosimod (0.05%) in a patient with neuropathic corneal pain. $OKYO #OKYOPharma #Biotech #Ophthalmology #Optometry #NCP #innovation okyopharma.com/fda-approves-c…

Watch interview with our new CEO Robert Dempsey. $OKYO #Opthalmology #CEO #Biotech #Optometry #NCP okyopharma.com/okyo-pharma-ap…

Exciting News from OKYO Pharma! Thrilled to announce Robert J. Dempsey as our new CEO, effective immediately! With 20+ years in ophthalmology, Robert led Shire's Global Ophthalmology & the landmark XIIDRA® deal, which was one of only three ophthalmology deals in the past twenty years with more than $1 billion upfront. The sale of Xiidra® to Novartis in 2019 included $3.4 billion upfront and up to an additional $1.9 billion in potential milestone payments, which was acquired 4 years later by Bausch + Lomb. His expertise will accelerate our lead asset urcosimod for neuropathic corneal pain (NCP) & ocular inflammation. Welcome, Robert—we're poised for growth. #OKYOPharma #Biotech #Ophthalmology #Optometry #Leadership #Innovation $OKYO okyopharma.com/okyo-pharma-ap…

OKYO Pharma ( $OKYO ) to ring the Nasdaq Opening Bell this morning! Join Executive Chairman Gabriele Cerrone and the team as we mark our progress in innovative therapies for neuropathic corneal pain. Live from 9:15am ET @NasdaqExchange @Nasdaq #NASDAQ nasdaq.com/marketsite/bel…

OKYO Pharma has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 24,551 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,516,297 shares. $OKYO okyopharma.com/okyo-pharma-an…

OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain. Patients treated with 0.05% urcosimod demonstrated not only a positive reduction in neuropathic corneal pain, but also favorable changes in corneal nerve structure which were not observed in the placebo group. $OKYO okyopharma.com/okyo-pharma-an…

OKYO Pharma Announces Chairman and Founder Acquires Shares. Gabriele Cerrone, Executive Chairman has acquired 27,051 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,491,746 shares. $OKYO okyopharma.com/okyo-pharma-an…